Upload
sariu-ali
View
484
Download
2
Embed Size (px)
DESCRIPTION
Anemia in CKD
Citation preview
ANEMIA IN CHRONIC KIDNEY DISEASE
Dr Sariu AliMedical Officer
Supervisor: Dr Ibrahim Shiham MBBS,MD,DM Nephrology
Contents Definition of CKD Stages of CKD Definition of anemia in CKD Effects of Anemia in patients with
CKD. Normal Erythropoiesis Causes of anemia in CKD. Evaluation of patients Iron therapy. ESA
Definition of Chronic Kidney
Disease
1. Kidney damage for 3 months with or without decreased GFR, manifest by either:
Pathological abnormalities; or
Markers of kidney damage, including abnormalities in the composition of the blood or urine, or abnormalities in imaging tests.
2. GFR <60 mL/min/1.73m2 for 3 months
Stages of CKD Stage GFR
(ml/min/1.73m2)
Description
1 > 90 Normal or increased GFR, with other evidence of kidney damage
2 60–89 Slight decrease in GFR, with other evidence of kidney damage
3a 45–59 Moderate decrease in GFR, with or without other evidence of kidney damage3b 30–44
4 15–29 Severe decrease in GFR, with or without other evidence of kidney damage
5 < 15 Established renal failure
Diagnosis should be on the basis of evidence of CKD for ≥ 3 months
Defining anaemia in CKDAge or gender group Hb below
(g/dl)
Children
6 months to 5 years 11.0
5 to 11 years 11.5
12 to 14 years 12.0
Women > 15 years
(non-pregnant)
12.0
Men > 15 years 13.0
Hb cut-off levels – World Health OrganizationKDIGO 2011
Effects of anemia (QOL)• QUALITY OF LIFE:
o Anemia results in poorer quality of life in patients with renal failure.
o This correlation can be proven by the poor quality of life scores in patients with lower Hb values.
o Many observational as well as RCT have positively demonstrated that the QOL scores improved in patients who were given ESA and iron to increase their Hb
Effects of anemia(mortality)• Generation of hypoxia due to anemia is poorly
tolerated in patients with preexisting cardiac and vascular diseases. Compensatory mechanisms leads to development of LVH.
• Observational studies do show an increase in mortality in patients with CKD but not direct casualty.
• Interventional studies (DOPPS) show that for an increase of 1g/dL of Hb results in 4% decline in mortality.
• Also, Medicare data show that CKD=100% and CKD+Anemia=270% in 2-yr mortality risk.
EFFECTS of anemia on CV health
• CV disease related mortality is 15 times more in patients with CKD.
• 50% of deaths in patients with CKD are due to CV disease.
• LVH is the most common abnormality seen in patients with CKD and there is a strong correlation between anemia and LVH.
• Tissue hypoxia due to anemia is the principal stimuli triggering the compensatory changes that stresses the CV system
Normal erythropoiesis
This activation promotes increased survival of precursor cells.
Normal Iron cycle
Prevalence of anemia in CKD
68
51.5
-5
WHAT CAUSES ANEMIAIN CHRONIC KIDNEY DISEASE?
Relative Erythropoietin (EPO) deficiency
Iron deficiency Blood loss Shortened red cell life span Vitamin deficiencies The “uremic milieu” /Bone marrow
suppression Inflammation Hyperparathyroidism
Unfortunately, we know little about the relative contributions of the different factors and conditions in the early stages of chronic kidney disease.
Relative EPO deficiency• Erythropoietin regulates Erythropoiesis• Glycosylated polypeptide
• 90% produced in the peritubular interstitial Fibroblasts like cells of kideny ,10 % in the liver
• No preformed stores
• Produced in response to low oxygen tension in the tissues of kidneys
CAUSES ANEMIAIN CKD
IDA in CKD • Blood loss from GI tract
• In HD patients : Repeated Blood Loss ; retention of Blood in Dialyzer and blood lines.
• Frequent Blood Sampling for Ix• Loss from Surgical Procedures ( vascular
access) • Interference with absorption due to Meds
( Gastric acid inhibitors ,Phosphate Binders )
Reduced absorption due to inflammation
CAUSES ANEMIAIN CKD
Blood loss
• Risk of blood loss due to platelet dysfunction.
• The main cause of blood loss is
dialysis, especially hemodialysis, and the loss results in absolute iron deficiency.
• Hemodialysis patients may lose 3 to 5 g of iron per year.
CAUSES ANEMIAIN CKD
Shortened red blood cell life span
• The life span of red cells is reduced by approximately one third in hemodialysis patients
CAUSES ANEMIAIN CKD
“uremic milieu”• The “uremic milieu” is a term that is overused in attempts to explain the multiple organ dysfunction of chronic kidney disease.
• In studies in vitro, the term has been invoked when cultured cells were exposed to serum from patients with chronic kidney disease,with results that mimicked some of the clinical observations.
• For example, “uremic” serum has been shown to inhibit primary bone marrow cultures of early erythroid cell lines.
CAUSES ANEMIAIN CKD
Diagnosis and evaluation of anemia in CKD
Age or gender group Hb below (g/dl)
Children
6 months to 5 years 11.0
5 to 11 years 11.5
12 to 14 years 12.0
Women > 15 years(non-pregnant)
12.0
Men > 15 years 13.0
When estimated glomerular filtration rate ( eGFR ) of less than 60 ml/min/1.73m2 should trigger investigation into whether anaemia is due to CKD
Preliminary investigations:
Complete blood count (CBC), red cell indices, white blood cell count, and differential, and platelet count
Absolute reticulocyte countSerum ferritin levelSerum transferrin saturation (TSAT)Serum vitamin B12 and folate levels
Iron status
Presence or Absence of Storage iron
Serum Ferritin
Availability of iron to support ongoing erythropoiesis
TSAT ;(serum Iron x 100)/TIBC
Use of iron to treat anemia in CKD
Iron supplementation is widely used in CKD patients:
To treat iron deficiencyPrevent its development in ESA treated
patientsRaise Hb levels in the presence or absence of
ESA treatmentReduce ESA doses in patients receiving ESA
treatment.
When to start iron therapy?For adult CKD patients with anemia not on iron or ESA therapy, a trial of IV iron (or in CKD ND patients alternatively a 1–3 month trial of oral iron therapy) if:
an increase in Hb concentration without starting ESA treatment is desired and
TSAT is <30% and ferritin is <500 ng/ml (<500 mg/l)
For adult CKD patients on ESA therapy who are not receiving iron supplementation, a trial of IV iron(or in CKD ND patients alternatively a 1–3 month trial of oral iron therapy) if :
an increase in Hb concentration or a decrease in ESA dose is desired and
TSAT is <30% and ferritin is <500 ng/ml (<500 mg/l)
• High ferritin levels in some studies have been associated with higher death rates, but whether elevation of ferritin levels is a marker of excessive iron administration rather than a nonspecific acute phase reactant is not clear.
• At increasingly higher ferritin levels, there is some evidence to indicate that hepatic deposition of iron increases
• Routine use of iron supplementation in patients with TSAT >30% or serum ferritin >500 ng/ml (>500mg/l) is not recommended
IV or Oral?
• Available evidence supports an efficacy advantage of IV compared with oral administration of iron although the effect is rather small.
• There is evidence supporting a preference for the IV route of iron administration in CKD 5HD patients
• IV iron administration led to a greater increase in Hb concentration, a lower ESA dose, or both.
• Oral iron is typically prescribed to provide approximately 200 mg of elemental iron daily
(for instance ferrous sulfate 325 mg three times daily; each pill provides 65 mg elemental iron).
Iron therpy• Oral formulations (sulfate, gluconate, fumarate,
polysaccharide complex)• Parenteral (iv) formulations (dextran, gluconate,
sucrose, ferric carboxy maltose).
• In patients with HD-CKD iv formulations are the only form to be used (KDOQI)
• Newer formulations are associated with significantly fewer side effects.
• Iv iron therapy should be guided by the iron status of the patient rather than empirical Rx. Approx 1000mg of Fe over 2-3 weeks is necessary to overcome the deficiency
Monitoring therapy
ESA Therapy
Erythropoietic Stimulating Agents (ESA) Recombinent erythropoietin : Trade names:
Epogen (EPO), Procrit
Darbepoietin alfaTrade name: Aranespo 3x longer half-life and greater biological activity
than recombinant erythropoietin. CERA
• Continuous Erythropoiesis Receptor Activator• A pegylated form of recombinant human
erythropoietin• Has the ability to repeatedly activate the
erythropoiesis receptor
Erythropoietic Stimulating Agents (ESA)
• Future therapies:o EPO mimetics
• Drugs that mimic the action of erythropoietinoShort peptide sequences (14 AA) that
bind to and activate the EPO receptor• Trade name = Hematide
When to start ESA ?
CKD NDHb > 10g/dL - ESA not to be initiated
Hb < 10g/dL - initiation of ESA therapy be individualized
CKD 5D ESA therapy should be initiated when
the Hb is between 9.0–10.0 g/dL
Address all correctable causes of anemia prior to initiation of ESA therapy.
HOW? Epoetin-alfa or epoetin-beta
20 -50 IU/kg three times a week.
(SC) or IV
Darbepoetin-alfa
0.45 mcg/kg once weeklyby subcutaneous
(SC) or IV
0.75 mcg/kg once every 2 weeks
SC
CERA 0.6 mg/kg once every 2 weeks
SC - CKD ND IV - CKD 5D
1.2 mg/kg once every 4 weeks by
SC - CKD ND For CKD 5HD patients and those on hemofiltration or hemodiafiltration therapy,
either IV or SC administration of ESA. For CKD ND and CKD 5PD patients, subcutaneous administration of ESA.
ESA Therapy
TARGET HB LEVEL: • Objective of initial ESA therapy is a rate of increase in (Hb) of
1.0 to 2.0 g/dl (10 to 20 g/l) per month
• Rise in Hb of > 2.0 g/dl (20 g/l) over a 4-week period should be avoided
• Target Hb ; not to exceed > 11.5g/dL
• HB initially monitored weekly , dose adjustment made every 4 weekly.
• Once stable HB achieved , monitor 4 weekly to 3 monthly , or in between any intercurrent illness or symptomatic.
ESA Therapy
DOSE MODIFICATION
If HB level increases by >1gm%/2wks, then reduce dose of EPO by 25%.
If HB level not increases by >1gm%/ mnth , then increase dose of EPO by 25%.
ESA Therapy
ADVERSE EVENTS OF rHuEPO:
Hypertension,-30% Hypertensive encephalopathy Vascular access failure Increase in pre dialysis CKP ,and potassium Increases risk of stroke in DM type 2.
ESA Therapy
References • Emed • Davidson • Kumar and clark • Harrisons • Anaemia management in chronic kidney disease
NICE clinical guideline 39
Thank you